Keytruda
Keytruda Receives Traditional Approval for Some Patients With HER2-Positive Gastric or GEJ Adenocarcinoma
The FDA has granted traditional approval to Keytruda with trastuzumab, fluoropyrimidine- and platinum-containing ...
MARCH 20, 2025
FDA Approves Keytruda With Chemo for Primary Advanced or Recurrent Endometrial Carcinoma
The FDA has approved Keytruda with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult ...
JUNE 18, 2024
Survival Benefit Seen With Adjuvant Therapy in Patients With ccRCC
Adjuvant pembrolizumab (Keytruda, Merck) significantly improved overall survival in patients with clear cell renal ...
FEBRUARY 15, 2024
Keytruda With Chemoradiotherapy Approved for FIGO 2014 Stage III-IVA Cervical Cancer
The FDA approved Keytruda with chemoradiotherapy for patients with FIGO 2014 stage III to IVA cervical cancer.
JANUARY 19, 2024
FDA Amends Keytruda’s Gastric Cancer Indication
The FDA revised the existing indication of pembrolizumab with trastuzumab-, fluoropyrimidine- and ...
NOVEMBER 15, 2023
FDA Approves Neoadjuvant/Adjuvant Keytruda for Resectable NSCLC
The FDA approved pembrolizumab (Keytruda, Merck) with platinum-containing chemotherapy as neoadjuvant treatment, ...
OCTOBER 17, 2023
Keytruda Granted Full Approval for MSI-H/dMMR Solid Tumors
The FDA granted full approval to pembrolizumab (Keytruda, Merck) for the treatment of adult and pediatric patients ...
APRIL 5, 2023
Padcev With Keytruda Approved for Locally Advanced or Metastatic Urothelial Carcinoma
The FDA gave accelerated approval to enfortumab vedotin-ejfv (Padcev, Astellas Pharma) with pembrolizumab ...
APRIL 5, 2023
Keytruda Approved for Adjuvant Treatment of Certain Kinds of NSCLC
The FDA has approved Keytruda for adjuvant treatment following resection and platinum-based chemotherapy for ...
FEBRUARY 3, 2023
Pembrolizumab Newly Indicated to Treat Advanced Endometrial Carcinoma
The FDA approved pembrolizumab (Keytruda, Merck) for the treatment of patients with microsatellite instability?high ...
MARCH 23, 2022
Pembrolizumab After Resection of Stage II Melanoma Reduces Recurrence Risk
In patients with resected stage IIB or IIC melanoma, adjuvant pembrolizumab (Keytruda, Merck) significantly reduces ...
JANUARY 12, 2022
FDA Grants New Indication for Keytruda as Adjuvant Therapy for Certain Melanoma Cases
The anti?PD-1 therapy is now approved for the adjuvant treatment of adults and children ages 12 years and older ...
DECEMBER 7, 2021